| Issue Date | Title | Author(s) |
| 2017-10-13 | Novel therapeutics for multiple sclerosis designed by parasitic worms | Dixit, A; Tanaka, A; Greer, JM; Donnelly, S |
| 2007-01-01 | Cell and gene therapy in Australia | Martiniello-Wilks, R; Rasko, JEJ |
| 2016-06-01 | TLR2, TLR4 AND MyD88 Mediate Allergic Airway Disease (AAD) and Streptococcus pneumoniae-Induced Suppression of AAD | Thorburn, AN; Tseng, HY; Donovan, C; Hansbro, NG; Jarnicki, AG; Foster, PS; Gibson, PG; Hansbro, PM |
| 2014-08-01 | TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future | Sedger, LM; McDermott, MF |
| 2018-12-01 | Gene therapy and type 1 diabetes mellitus | Chellappan, DK; Sivam, NS; Teoh, KX; Leong, WP; Fui, TZ; Chooi, K; Khoo, N; Yi, FJ; Chellian, J; Cheng, LL; Dahiya, R; Gupta, G; Singhvi, G; Nammi, S; Hansbro, PM; Dua, K |
| 2019-05-01 | Current Status on Immunological Therapies for Type 1 Diabetes Mellitus | Xin, GLL; Khee, YP; Ying, TY; Chellian, J; Gupta, G; Kunnath, AP; Nammi, S; Collet, T; Hansbro, PM; Dua, K; Chellappan, DK |
| 2014-08-01 | Cytokines and cytokine receptors as immunotherapeutics: Humble beginnings and exciting futures | Sedger, LM; Seddiki, N; Ranasinghe, C |
| 2003-06-01 | Genomics and its impact on parasitology and the potential for development of new parasite control methods | Ellis, JT; Morrison, DA; Reichel, MP |
| 2017-06 | In vivo effector functions of high-affinity mouse IgG receptor FcγRI in disease and therapy models. | Gillis, CM; Zenatti, PP; Mancardi, DA; Beutier, H; Fiette, L; Macdonald, LE; Murphy, AJ; Celli, S; Bousso, P; Jönsson, F; Bruhns, P |
| 2017-05-15 | Attenuating immune pathology using a microbial-based intervention in a mouse model of cigarette smoke-induced lung inflammation | Bazett, M; Biala, A; Huff, RD; Zeglinksi, MR; Hansbro, PM; Bosiljcic, M; Gunn, H; Kalyan, S; Hirota, JA |
